Biopharmaceutical company Aridis Pharmaceuticals Inc (Nasdaq:ARDS) stated on Friday that its CEO, Dr Vu Truong, will participate in Cantor Fitzgerald's Virtual Symposium: "Winning Ways to Treat Infections and COVID-19" to be held on 30 June 2020 at 11:00 ET
The company said it has generated multiple clinical stage mAbs targeting bacteria that cause life-threatening ventilator associated pneumonia (VAP) and preclinical stage antiviral mAbs.
In addition, the company's pipeline also includes AR-701 (COVID-19), a fully human mAb cocktail discovered from convalescent COVID-19 patients that are directed at multiple envelope proteins on SARS-CoV-2. AR-201 (RSV infection). The AR-201 is a fully human IgG1 mAb out-licensed preclinical programme aimed at neutralizing diverse clinical isolates of respiratory syncytial virus (RSV).
UCB announces BIMZELX (bimekizumab-bkzx) three-year data at EULAR 2025
Sanofi expedites Beyfortus shipments to support early RSV season readiness
Mediar Therapeutics reports first IPF patient dosed in MTX-463 Phase 2 trial
Innovent's IBI363 granted second breakthrough therapy designation in China
bioMérieux launches rapid PCR test for equine respiratory diseases
BioNTech and Bristol Myers Squibb partner to co-develop bispecific antibody for solid tumours
Taiho Oncology and Cullinan Therapeutics report REZILIENT1 Phase 1/2 data